๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca104 Eli Lilly and Company87 Merck Sharp & Dohme LLC70 Janssen Research & Development, LLC67 AbbVie66
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Georgia

2350 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
NCT07300969Major Depressive Disorder (MDD)
DrugDT-101
Draig Therapeutics Ltd
Phase 2
300
Arkansas, California, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nevada
2025-12-16
Recruiting
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818Schizophrenia
DrugNBI-1117568
Neurocrine Biosciences
Phase 3
560
California, Florida, Georgia, Massachusetts, Mississippi, New York, Washington
2025-12-16
Recruiting
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
NCT07276581Rheumatoid Arthritis
AstraZeneca
Phase 2
320
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-15
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
1,035
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-15
Recruiting
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy, Sickle Cell Disease
Beam Therapeutics Inc.
Observational
50
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugPemetrexed
Revolution Medicines, Inc.
Phase 3
500
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-12-15
Recruiting
A Study of a Thyroid Hormone Receptor Beta Isoform (THRฮฒ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07288138Metabolic Dysfunction-associated Steatohepatitis
DrugECC4703
Eccogene
Phase 2
160
Arizona, Arkansas, California, Florida, Georgia, Indiana, Louisiana, Maryland
2025-12-15
Recruiting
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
NCT07221851Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Ascendis Pharma A/S
Phase 3
186
California, Colorado, Delaware, Florida, Georgia, Idaho, Louisiana, Minnesota
2025-12-12
Recruiting
NV PSR INSPIRE-A Pipelineโ„ข Vantage Post Approval Study
NCT06604884Intracranial Aneurysm
Medtronic Neurovascular Clinical Affairs
Observational
118
Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri, South Carolina
2025-12-12
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota
2025-12-11
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site
DrugsPF-08634404·Bevacizumab
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-12-11
Recruiting
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
NCT07214571Respiratory Syncytial Virus Infections
Shionogi
Phase 2
192
California, Florida, Georgia, Massachusetts, Missouri, New York, North Carolina, Ohio
2025-12-11
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2025-12-10
Recruiting
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
NCT07195591Glioblastoma
DrugTemozolomide
GT Medical Technologies, Inc.
Phase 3
766
Arizona, Georgia, Maryland, New Hampshire, New Jersey, New York, North Carolina, Pennsylvania
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2025-12-10
Recruiting
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
NCT07282665Clostridoides Difficile Associated Disease
Pfizer
Phase 3
32,500
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2025-12-10
Recruiting
PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
NCT06602271Postoperative Pain, Acute
DrugPF614
Ensysce Biosciences
Phase 3
320
Georgia, Texas, Utah
2025-12-09
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 3
466
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2025-12-09
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEYยฎ Kids)
NCT07107945Chronic Kidney Disease
DrugsJardiance·Empagliflozin
Boehringer Ingelheim
Phase 3
120
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2025-12-09
Active, closed
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
NCT07222917Chronic Kidney Disease and Hypertension
DrugBaxdrostat/dapagliflozin
AstraZeneca
Phase 2
222
Arizona, Florida, Georgia, Illinois, Kansas, North Carolina, Ohio, Pennsylvania
2025-12-05
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-12-04
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Mississippi
2025-12-03
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-03
Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453Plaque Psoriasis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Recruiting
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638Focal Segmental Glomerulosclerosis
Akebia Therapeutics
Phase 2
60
California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan
2025-12-03
Active, closed
A Study of DII235 in Adults With Elevated Lipoprotein(a)
NCT07235046Lipoprotein Disorder
Novartis Pharmaceuticals
Phase 2
234
Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-02
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
Recruiting
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
NCT07116031Chronic Graft Versus Host Disease
DrugBelumosudil
Sanofi
Phase 2
37
California, District of Columbia, Georgia, Massachusetts, New York, Texas, Washington
2025-12-02
Recruiting
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
NCT07395232Atopic Keratoconjunctivitis
DrugDFL24498
Dompรฉ Farmaceutici S.p.A
Phase 3
153
Florida, Georgia, Missouri, New York, North Carolina, Tennessee, Texas
2025-12-01
By invitation
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
NCT07222605Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
eQ8Health Corporation d/b/a CareONE Concierge
Not applicable
1,000
Georgia
2025-12-01
Active, closed
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults โ‰ฅ50 Years With Immunobridging to Adults 18-49
NCT07284654Pneumococcal Vaccines
Drugs31-valent pneumococcal conjugate vaccine·Capvaxive·PCV20
Vaxcyte, Inc.
Phase 3
4,049
Alabama, Arizona, California, Florida, Georgia, Indiana, Kansas, Louisiana
2025-12-01
Recruiting
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
NCT07296484Type 2 Diabetes, Cortisol Excess
DrugClofutriben
Sparrow Pharmaceuticals
Phase 2
1,500
Arizona, California, Florida, Georgia, Idaho, Illinois, Iowa, Kansas
2025-11-29
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
DrugRina-S
Genmab
Phase 3
660
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-11-28
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naรฏve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsCabazitaxel·Xaluritamig·Abiraterone acetate·Paclitaxel
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York
2025-11-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
NCT07233239Focal Seizures
DrugCbd-Os
Jazz Pharmaceuticals
Phase 1
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Michigan
2025-11-26
Recruiting
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
Active, closed
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
NCT07266558SARS-CoV-2
DrugsMRNA-1273·MRNA-1283
ModernaTX, Inc.
Phase 4
30,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-26
By invitation
Observational Study of VYKATโ„ข XR in Patients With Prader-Willi Syndrome
NCT07450664Prader-Willi Syndrome
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Georgia, Illinois, Indiana, Massachusetts, Michigan
2025-11-26
Recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington
2025-11-25
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531Type 1 Diabetes
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
By invitation
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07256392Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
1,370
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-11-25
Recruiting
A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions.
NCT07225751Ankle Arthrodesis or Arthroplasty, Hindfoot Fusion, Ankle Deformity, Ankle Disease
Kuros Biosurgery AG
Not applicable
126
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Virginia
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-24
Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
NCT07286175Bipolar Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 2
400
California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Pennsylvania
2025-11-24
Recruiting
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
NCT07209462Fragile X Syndrome
Mirum Pharmaceuticals, Inc.
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-11-22
Recruiting
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
NCT06971939Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals
Phase 4
234
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-21
Active, closed
Efficacy and Safety of NVX-CoV2705
NCT07086222COVID-19, Sars-CoV-2 Infection
Novavax
Phase 4
6,500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-11-20
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Phase 2
26
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-11-19
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Alabama, Florida, Georgia, Idaho, Massachusetts, Texas
2025-11-19
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
Arizona, California, Connecticut, Florida, Georgia, Iowa, Kentucky, Louisiana
2025-11-19
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
DrugsLeucovorin·Oxaliplatin·Bevacizumab
Summit Therapeutics
Phase 3
600
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-18
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT07290803Atopic Dermatitis
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
Recruiting
A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population
NCT07006831Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function
Devyser Inc.
Observational
400
California, Georgia, Maryland, Massachusetts, Utah
2025-11-14
Active, closed
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390Hidradenitis Suppurativa
DrugRitlecitinib
Pfizer
Phase 2
128
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kansas
2025-11-13
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
Recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
800
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-11-12
Recruiting
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07281079Phelan-McDermid Syndrome
DrugNNZ-2591
Neuren Pharmaceuticals Limited
Phase 3
160
Alabama, California, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-12
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627Ovarian Cancer
DrugINCB123667
Incyte Corporation
Phase 2
160
Alabama, California, District of Columbia, Florida, Georgia, Indiana, Iowa, Kentucky
2025-11-12
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-11-11
Recruiting
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
NCT07112378Eosinophilic Esophagitis (EoE)
DrugDupilumab
Regeneron Pharmaceuticals
Phase 3
20
Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2025-11-10
Recruiting
Mom Multi Postnatal Supplementation Trial
NCT07303595Postnatal Care
Perelel Inc.
Not applicable
80
Georgia
2025-11-10
Active, closed
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
NCT07187115Atrial Fibrillation (AF), Persistant Atrial Fibrillation
Boston Scientific Corporation
Not applicable
699
Arkansas, California, Georgia, Idaho, New York, Ohio, Pennsylvania, Texas
2025-11-07
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
DrugBrivekimig
Sanofi
Phase 2
208
Arizona, California, Florida, Georgia, Iowa, Louisiana, Missouri, Nevada
2025-11-06
Recruiting
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
NCT07206225Non-muscle Invasive Bladder Cancer
Pfizer
Phase 1
294
Alabama, Florida, Georgia, Illinois, Iowa, Kansas, New Jersey, New York
2025-11-06
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
DrugAZD0292
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
DrugSurabgene Lomparvovec
AbbVie
Phase 3
561
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2025-11-05
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada
2025-11-05
Recruiting
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
NCT07089576Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
Artivion Inc.
Not applicable
132
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-11-04
Recruiting
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644Hidradenitis Suppurativa (HS)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2/3
210
Arizona, California, Florida, Georgia, Indiana, Kentucky, Louisiana, Michigan
2025-11-03
Recruiting
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 1
24
Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-11-03
Recruiting
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
NCT07223840Smoking
DrugBrenipatide
Eli Lilly and Company
Phase 2
222
Arkansas, Florida, Georgia, Michigan, Missouri, Nevada, New York, South Carolina
2025-11-03
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-11-03
Recruiting
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
NCT07216742Infertility (IVF Patients)
Granata Bio Corporation
Phase 3
659
California, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Maryland
2025-11-01
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDatopotamab deruxtecan·Dato-DXd·Paclitaxel
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois
2025-10-31
Recruiting
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
NCT07142356Uncontrolled Hypertension
Retension Pharmaceuticals. Inc.
Phase 2
280
Alabama, Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Nevada
2025-10-31
Active, closed
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
NCT06851559Eosinophilic Esophagitis
DrugVonoprazan
Phathom Pharmaceuticals, Inc.
Phase 2
95
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2025-10-30
By invitation
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
NCT07217860Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, New Jersey, New York, Pennsylvania
2025-10-30
Recruiting
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
NCT07123155Pompe Disease
Shionogi
Phase 2
45
California, Florida, Georgia, Missouri, North Carolina, Ohio, Pennsylvania, Virginia
2025-10-30
Recruiting
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
NCT07327840Lipoprotein Disorder
Kylonova (Xiamen) Biopharma co., LTD.
Phase 2
204
California, Florida, Georgia, Louisiana, Nevada, North Carolina
2025-10-29
Recruiting
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
NCT06934967Paroxysmal Nocturnal Hemoglobinuria (PNH)
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
12
Georgia, New Jersey, Pennsylvania, Tennessee
2025-10-28
Recruiting
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
NCT07207369Acne Scars
AbbVie
Phase 3
395
Arizona, California, Connecticut, Georgia, Maryland, New York, North Carolina, Texas
2025-10-24
Recruiting
BoxX-NoAF Clinical Trial
NCT06989775Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
AtriCure, Inc.
Not applicable
960
Arkansas, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-10-24
Recruiting
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,200
Arizona, Arkansas, California, Colorado, Florida, Georgia, Kansas, Louisiana
2025-10-24
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Pembrolizumab
Daiichi Sankyo
Phase 3
686
Alaska, California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Minnesota
2025-10-24
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Kansas
2025-10-23
Recruiting
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
NCT07220811Ig-E Mediated Food Allergy
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Phase 2
100
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Massachusetts
2025-10-22
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
DrugsMIRV·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
Eli Lilly and Company
Phase 3
1,630
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-10-22
Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
NCT07069738Heart Failure - NYHA II - IV
Boston Scientific Corporation
Not applicable
850
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois
2025-10-22
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
1,196
California, Colorado, Florida, Georgia, Idaho, Kentucky, Louisiana, Maine
2025-10-20
Recruiting
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
NCT07175428Atrial Fibrillation (AF)
DrugsREGN9933·Cenvacibart·Apixaban
Regeneron Pharmaceuticals
Phase 2
1,200
Alabama, California, Florida, Georgia, Indiana, Louisiana, Maryland, Massachusetts
2025-10-20
Recruiting
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
NCT07143669Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
Blueprint Medicines Corporation
Observational
750
Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2025-10-17
Recruiting
ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury
NCT07147296Spinal Cord Injuries, Blood Pressure Disorders
ONWARD Medical, Inc.
Not applicable
60
Arkansas, Colorado, Florida, Georgia, Kentucky, Maryland, Massachusetts, Minnesota
2025-10-17
Recruiting
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
NCT07215559Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsMacupatide·Eloralintide
Eli Lilly and Company
Phase 2
200
Arizona, Florida, Georgia, Nevada, New Jersey, Ohio, Texas, Utah
2025-10-16
Recruiting
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963NMIBC
ImmunityBio, Inc.
Phase 1/2
40
Arizona, California, Georgia, Michigan, New York, Pennsylvania, Tennessee, Virginia
2025-10-15
Recruiting
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
NCT07115004Von Willebrand Disease (VWD)
DrugVGA039
Vega Therapeutics, Inc
Phase 3
60
Arkansas, California, Connecticut, Georgia, Michigan, Minnesota, North Carolina, Pennsylvania
2025-10-15
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-10-15
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer
DrugJSB462
Novartis Pharmaceuticals
Phase 1/2
188
Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington
2025-10-15
Rows per page Showing 401–500 of 2350
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia?page=5

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,350 of those studies with a site in Georgia.

How many clinical trials are recruiting in Georgia?

1,212 of the 2,350 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 40 have not yet opened recruitment, 1,038 are active but closed to new participants, and 60 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.